MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/diagnostics12020539

Медицинская библиотека · Diagnostics (Basel, Switzerland) · 2022

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Gourari Karim, Catherine Julien, Garaud Soizic, Kerger Joseph, Lepida Antonia, Georgala Aspasia, Lebrun Fabienne, Gomez Galdon Maria, Gil Thierry, Willard-Gallo Karen, Langouo Fontsa Mireille

Клинический случайСтатьяПеревод в очереди

Аннотация

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report a patient with advanced metastatic ccRCC, who developed grade 4 cholestasis during combined therapy with nivolumab and cabozantinib. After the exclusion of common disorders associated with cholestasis and a failure of corticosteroids (CS), a liver biopsy was performed that demonstrated severe ductopenia. Consequently, a diagnosis of vanishing bile duct syndrome related to TKI and ICI administration was made, resulting in CS discontinuation and ursodeoxycholic acid administration. After a 7-month follow-up, liver tests had returned to normal values. Immunological studies revealed that our patient had developed robust T-cells and macrophages infiltrates in his lung metastasis, as well as in skin and liver tissues at the onset of toxicities. At the same time, peripheral blood immunophenotyping revealed significant changes in T-cell subsets, suggesting their potential role in the pathophysiology of the disease.

Для цитирования: Gourari Karim, Catherine Julien, Garaud Soizic, Kerger Joseph, Lepida Antonia, Georgala Aspasia, Lebrun Fabienne, Gomez Galdon Maria, Gil Thierry, Willard-Gallo Karen, Langouo Fontsa Mireille. A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.. Diagnostics (Basel, Switzerland). 2022. DOI: 10.3390/diagnostics12020539.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.